NFAT and IL-3: A Study of Immune Regulation and Potential Drug Targets

Target Name: ILF3

NCBI ID: G3609

ILF3

NFAT and IL-3: A Study of Immune Regulation and Potential Drug Targets

The interleukin-3 (IL-3) protein is a key regulator of immune responses and has been implicated in a variety of diseases, including autoimmune disorders, cancer, and neurodegenerative diseases. The nuclear factor of activating T cells (NFAT) is a transcription factor that regulates the expression of IL-3. NFAT has three functional subunits: NFAT1, NFAT2, and NFAT3. The nuclear factor of activating T cells (NFAT) is a transcription factor that regulates the expression of IL-3. NFAT has three functional subunits: NFAT1, NFAT2, and NFAT3. The study of NFAT and its subunits has been an active area of research in recent years, with a focus on understanding its role in disease and developing new treatments.

IL-3 as a drug target

IL-3 has been identified as a potential drug target for a variety of diseases, including autoimmune disorders, cancer, and neurodegenerative diseases. IL-3 is a key regulator of immune responses and has been shown to play a role in the development and progression of autoimmune diseases. For example, studies have shown that IL-3 is involved in the regulation of T cell development and activation, and that its levels are elevated in individuals with autoimmune disorders.

In addition to its role in immune regulation, IL-3 has also been shown to play a role in the development and progression of cancer. For example, studies have shown that IL-3 is involved in the regulation of cell survival and that its levels are elevated in cancer cells. This suggests that IL-3 may be a useful target for cancer treatments.

IL-3 has also been shown to be involved in the development and progression of neurodegenerative diseases. For example, studies have shown that IL-3 is involved in the regulation of neuron survival and that its levels are elevated in individuals with neurodegenerative diseases. This suggests that IL-3 may be a useful target for neurodegenerative disease treatments.

The potential benefits of targeting IL-3

Targeting IL-3 as a drug target has the potential to treat a variety of diseases. For example, IL-3 has been shown to be involved in the regulation of immune responses, and treatments that target IL-3 have been shown to be effective in treating autoimmune disorders. Additionally, IL-3 has been shown to play a role in the development and progression of cancer, and treatments that target IL-3 have been shown to be effective in treating cancer. Finally, IL-3 has also been shown to be involved in the development and progression of neurodegenerative diseases, and treatments that target IL-3 have been shown to be effective in treating neurodegenerative diseases.

IL-3 as a biomarker

IL-3 has also been used as a biomarker for a variety of diseases. For example, studies have shown that IL-3 levels are elevated in individuals with autoimmune disorders, and that treatments that target IL-3 have been shown to be effective in treating these disorders. Additionally, IL-3 has been shown to be involved in the regulation of cell survival, and biomarkers that measure cell survival have been used to diagnose and monitor a variety of diseases, including cancer.

IL-3 as a drug

In addition to its potential as a biomarker, IL-3 has also been identified as a potential drug target for a variety of diseases. For example, studies have shown that IL-3 is involved in the regulation of immune responses, and that treatments that target IL-3 have been shown to be effective in treating autoimmune disorders. Additionally, IL-3 has been shown to play a role in the development and progression of cancer, and treatments that target IL-3 have been shown to be effective in treating cancer. Finally, IL-3 has also been shown to be involved in the development and progression of neurodegenerative diseases, and treatments that target IL-3 have been shown to be effective in treating neurodegenerative diseases.

Conclusion

In conclusion, IL-3 is a protein that plays

Protein Name: Interleukin Enhancer Binding Factor 3

Functions: RNA-binding protein that plays an essential role in the biogenesis of circular RNAs (circRNAs) which are produced by back-splicing circularization of pre-mRNAs. Within the nucleus, promotes circRNAs processing by stabilizing the regulatory elements residing in the flanking introns of the circularized exons. Plays thereby a role in the back-splicing of a subset of circRNAs (PubMed:28625552). As a consequence, participates in a wide range of transcriptional and post-transcriptional processes. Binds to poly-U elements and AU-rich elements (AREs) in the 3'-UTR of target mRNAs (PubMed:14731398). Upon viral infection, ILF3 accumulates in the cytoplasm and participates in the innate antiviral response (PubMed:21123651, PubMed:34110282). Mechanistically, ILF3 becomes phosphorylated and activated by the double-stranded RNA-activated protein kinase/PKR which releases ILF3 from cellular mature circRNAs. In turn, unbound ILF3 molecules are able to interact with and thus inhibit viral mRNAs (PubMed:21123651, PubMed:28625552)

The "ILF3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ILF3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets